trending Market Intelligence /marketintelligence/en/news-insights/trending/_puo91lgxucger-cxnj8nw2 content esgSubNav
In This List

Teva ends testing of fremanezumab for chronic cluster headache

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Teva ends testing of fremanezumab for chronic cluster headache

Teva Pharmaceutical Industries Ltd. will end human testing of fremanezumab as a treatment for chronic cluster headache after an analysis determined that the study was unlikely to meet its main goal.

Testing of the drug as a therapy for episodic cluster headaches will continue, the Israeli drugmaker said in a June 15 statement. Fremanezumab is under review by U.S. and EU regulators as a quarterly or monthly injection for the prevention of migraines in adults.

"While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine," Tushar Shah, senior vice president and head of global specialty clinical development at Teva, said in the statement.

Fremanezumab belongs to a group of medicines known as calcitonin gene-related peptide, or CGRP, inhibitors. The group includes Eli Lilly and Co.'s galcanezumab and Amgen Inc. and Novartis AG's Aimovig, which won U.S. approval in May.